Laser Photonics Expands Pharmaceutical Presence with $1.3 Million High-Speed Laser System Contract

Orlando, Thursday, 22 January 2026.
On January 22, 2026, Laser Photonics Corporation (NASDAQ: LASE) validated its expanding footprint in the pharmaceutical sector by securing a $1.3 million order for its specialized TD-140 laser drilling system. This contract with a new international client highlights the company’s ability to meet rigorous FDA manufacturing standards, utilizing technology capable of processing 140,000 tablets per hour. For market observers, this deal represents a critical step in revenue diversification and operational growth, signaling that Laser Photonics is successfully translating its industrial laser capabilities into the high-stakes medical manufacturing arena following recent executive leadership adjustments.